Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients

Jiabo Di,1 Leon F.A.G. Massuger,2 Tjitske Duiveman-de Boer,1 Petra L.M. Zusterzeel,2 Carl G. Figdor1 and Ruurd Torensma1,*

1Department of Tumor Immunology; Nijmegen Centre for Molecular Life Sciences; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands; 2Department of Obstetrics and Gynecology; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands

Keywords: ovarian cancer, stem cell markers, CD4, CD8, IP-10, proliferation

The identification of growth and differentiation pathways that are responsible for the proliferation and survival of cancer stem cells (CSCs) has opened avenues for the discovery of novel therapeutic targets. In the initial phase of an anticancer immune response, T cells specific for tumor-associated antigens develop in patients and, at least under selected circumstances, are able to eliminate malignant cells. However, it remains unknown whether CSC-specific T cells are also operational. We found naturally occurring multifunctional CD4+ and CD8+ T cells specific for the stem cell marker OCT4 among the peripheral blood mononuclear cells (PBMCs) of both healthy individuals and ovarian cancer patients. Moreover, lymphocytes isolated from the ascites of patients affected by ovarian malignancies also contained OCT4-specific T cells. OCT4-reactive CD4+ T cells did not produce interferon γ (IFNγ) and IFNγ-inducible protein 10 (IP-10) but were capable of proliferation upon stimulation with dendritic cells (DCs) loaded with an OCT4-derived peptide or OCT4 mRNA. OCT4-reactive CD8+ cells did not proliferate in response to a similar challenge, yet produced IP-10 as well as sufficient amounts of IFNγ to induce IP-10. Furthermore, CD8+ cytotoxic T cells were able to release their lysosomal components, as indicated by the mobilization of CD107a. These results demonstrate the existence of anti-CSC specific T cells in ovarian cancer patients.

Introduction

The immune system has the potential to recognize and destroy aberrant cells before they form large tumors (reviewed in ref. 1). However, cancer cells often avoid immunological elimination, either as the immune system fails to recognize them or as they actively stimulate immunosuppressive processes.2 Tumor-infiltrating T cells specific for tumor-associated antigens (TAAs) are frequently detected in cancer patients.3 During disease progression, different types of T cells are recruited to the neoplastic lesion, including CD4+ T cells, CD8+ T cells, CD3’CD56+ T cells, Th17 cells, natural killer (T) cells and regulatory T cells (Tregs).4,5 An effective antitumor immune response consists of the direct killing of tumor cells by CD8+ cytotoxic T lymphocytes (CTLs), which recognize TAAs presented in complex with MHC Class I molecules. Spontaneous tumor-targeting CD8+ T cells have been identified in various malignancies, including melanoma, adenocarcinoma and leukemia (reviewed in ref. 6). The antigenic targets of these T cells include mutated proteins, embryonic proteins that are selectively re-expressed by malignant cells as well as overexpressed proteins that - when expressed at normal levels - are not presented on MHC Class I molecules.7 Several TAAs that can be recognized by T cells have also been identified in ovarian tumors.8 However, most of these TAAs are not tumor-specific but rather shared with normal tissues.

Upon antigenic stimulation, T cells secrete cytokines, proliferate and proceed to develop into CTLs. Activated CD4+ and CD8+ T cells express newly synthesized activation markers such as CD137, a co-stimulatory molecule that is induced as a result of antigen-specific T-cell activation. The expression of CD137 correlates with the functional activation of CD8+ T cells as well as with the differentiation of effector and memory CD8+ T cells. Moreover, tumor-lytic T cells are enriched in the CD137+ cell population.9–11 The predominant mechanism of tumor killing by CTLs is perforin-granzyme dependent (reviewed in ref. 12). The acquisition of cell surface CD107a by CD8+ T cells indicates that these cells have secreted intracellular perforin as a result of activation-induced degranulation.12 Alongside, antigen-reactive T cells secrete multiple cytokines including (but not limited to) interferon γ (IFNγ) and tumor necrosis factor α (TNFα), which can stimulate MHC Class I expression on tumor cells and hence increase their sensitivity to the effector functions of CTLs. IFNγ may also activate macrophages to directly kill tumor cells (reviewed in ref. 14).

The recent identification of growth and differentiation pathways that are responsible for the proliferation and survival of cancer stem cells (CSCs) has unveiled novel therapeutic targets.
CSCs (or tumor-initiating cells) are rare tumor cells with the ability to self-renew and give rise to phenotypically diverse tumor-cell populations. Increasing experimental evidence suggests that CSCs are responsible for initiating tumor growth and promoting metastasis in many different types of cancer, including ovarian carcinoma.\textsuperscript{15–26} However, evidence supporting the existence of CSC-targeting adaptive immune responses is scarce. We have previously shown that OCT4+MYC+NANOG\textsuperscript{+} cells constitute putative ovarian CSCs. OCT4 is an embryonic stem cell-specific transcription factor that is expressed at high levels by undifferentiated human embryonic stem cells (ESCs) and is downregulated upon differentiation.\textsuperscript{27–29} Furthermore, patients affected by germ cell tumors appear to harbor OCT4\textsuperscript{+} cells,\textsuperscript{30} and T cells specific for this CSC-specific antigen have been documented in a high percentage of healthy individuals.\textsuperscript{31,32} The hypothetical absence of OCT4-specific T cells from the circulation of ovarian cancer patients might hence reflect another mechanism whereby ovarian tumor escape immunosurveillance.

As reported here, we detected low frequencies of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells specific for OCT4 in a high percentage of healthy donors as well as all ovarian cancer patients tested in this respect. Moreover, we found that these OCT4-specific T cells, which could also be isolated from tumor-associated ascitic fluids, are cytotoxic and can be expanded in vitro.

**Results**

**OCT4-specific IP-10 production by peripheral blood mononuclear cells of healthy subjects.** To assess the capacity of T cells to recognize OCT4, peripheral blood mononuclear cells (PBMCs) from healthy donors were either cultured with medium only, either stimulated with phytohemagglutinin (PHA, as a positive control) or stimulated with the immunoreactive OCT4-derived peptide 74 from Dhodapkar’s OCT4 peptide library.\textsuperscript{32} Endogenous CXCL10 (also known as IFN\textgamma-inducible protein-10, IP-10) was not observed in CD4\textsuperscript{+} T cells, CD8\textsuperscript{+} T cells, B cells and monocytes prior to stimulation (Fig. 1A), as cells cultured with medium only showed only background staining. Conversely, upon stimulation with the immunoreactive OCT4-derived peptide for 48 h, CD11c\textsuperscript{+} cells expressed high levels of intracellular IP-10. Of note, IP-10 was hardly detectable in CD8\textsuperscript{+} cells exposed to an OCT4-derived peptide (Fig. 1B). Next, we omitted brefeldin A from the experimental setting to assess IP-10 secretion. After 48 h of stimulation with the immunoreactive OCT4-derived peptide, IP-10 was detectable in two culture supernatants corresponding to 6 out of 12 donors (Fig. 2A). Furthermore, patients affected by germ cell tumors appear to harbor OCT4\textsuperscript{+} cells, and T cells specific for this CSC-specific antigen have been documented in a high percentage of healthy individuals.\textsuperscript{31,32} The hypothetical absence of OCT4-specific T cells from the circulation of ovarian cancer patients might hence reflect another mechanism whereby ovarian tumor escape immunosurveillance.

As reported here, we detected low frequencies of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells specific for OCT4 in a high percentage of healthy donors as well as all ovarian cancer patients tested in this respect. Moreover, we found that these OCT4-specific T cells, which could also be isolated from tumor-associated ascitic fluids, are cytotoxic and can be expanded in vitro.

To analyze the functional characteristics of OCT4-reactive CD8\textsuperscript{+} T cells in vitro. To analyze the functional characteristics of OCT4-reactive CD8\textsuperscript{+} T cells in vitro.
concentrations ranged from 210 to 564 pg/mL. Comparable results were obtained when CD8+ cells were stimulated by DCs loaded with the OCT4 mRNA (Fig. 2B). Remarkably, CD8+ T cells did not produce IP-10 in response to anti-CD3/anti-CD28 beads (Fig. 2), which is in accordance with data highlighting fundamental differences in the immunobiology of CD4+ and CD8+ cells. Further supporting this notion, it has recently been demonstrated that optimal TNFα and IFNγ responses by CD8+ cells exposed to anti-CD3 monoclonal antibodies require the simultaneous activation of CD26-transduced signals.34

T cells in vitro, MACS-sorted CD8+ T cells were stimulated with autologous DCs loaded with the immunoreactive OCT4-derived peptide 74. CD8+ T cells stimulated with unloaded autologous DCs and CD8+ T cells exposed to anti-CD3/anti-CD28 beads were used as a negative and positive control, respectively.

**IP-10 production.** CD8+ T cells were co-cultured for 2 d in the presence of autologous DCs that had been loaded with an immunoreactive OCT4-derived peptide, followed by the assessment of IP-10 secretion. IP-10 was detected in the co-culture supernatants corresponding to 10 out of 12 healthy donors (Fig. 2A). IP-10 concentrations ranged from 210 to 564 pg/mL. Comparable results were obtained when CD8+ cells were stimulated by DCs loaded with the OCT4 mRNA (Fig. 2B). Remarkably, CD8+ T cells did not produce IP-10 in response to anti-CD3/anti-CD28 beads (Fig. 2), which is in accordance with data highlighting fundamental differences in the immunobiology of CD4+ and CD8+ cells. Further supporting this notion, it has recently been demonstrated that optimal TNFα and IFNγ responses by CD8+ cells exposed to anti-CD3 monoclonal antibodies require the simultaneous activation of CD26-transduced signals.34

![Figure 1. OCT4-specific IP-10 production in peripheral blood mononuclear cells from healthy subjects.](image-url)
**IFNγ secretion and proliferation.** Similar to CD4+ T cells, CD8+ T cells exposed to OCT4-derived peptide-loaded DCs failed to exhibit a significantly increased secretion of IFNγ. This held true for the CD8+ T cells of all 12 healthy donors (Fig. 4A). Given the high levels of IP-10 observed in culture supernatants, we assume that IFNγ was secreted but rapidly consumed to stimulate IP-10 production. Antigen-dependent T-cell proliferation was examined 5 or 6 d upon stimulation, and CD8+ T cells exposed to autologous DCs loaded with an immunoreactive OCT4-derived peptide invariably failed to incorporate a significantly greater amount of 3[H]-thymidine than CD8+ T cells maintained in control conditions (Fig. 4A and Table S2). To exclude the non-reactivity to the single OCT4-derived peptide, CD8+ T cells were also exposed to autologous DCs that had previously been electroporated with the OCT4 mRNA, yielding similar results (data not shown). Taken together, these findings indicate that OCT4-specific CD8+ T cells are rare in healthy individuals and that the proliferative capacity of these cells upon in vitro stimulation is poor (Table S2). These results also indicate that CD8+ T cells can be activated in vitro by specific OCT4-derived peptides, leading to the production of IP-10.

**Functionality after re-stimulation.** Approximately 12 d after the first stimulation, CD8+ T cells were restimulated with DCs loaded with an immunoreactive OCT4-derived peptide, in order to examine the existence of multifunctional CD8+ T cells. Staphylococcal enterotoxin B (SEB)-exposed CD8+ T cells and previously stimulated CD8+ T cells cultured in standard conditions served as a positive and negative control, respectively. After 5 h of stimulation, CD8+ T cells were assessed for CD107a mobilization as well as for the expression of IFNγ and TNFα, while CD137 expression was measured upon overnight stimulation. CD137-expressing CD8+ T cells were for 8 out of 9 donors investigated in this respect, while CD107a mobilization coupled to the expression of IFNγ and TNFα was detected in the CD8+ T cells of 4 out of 6 donors tested. The gating strategy and results from a representative donor are shown in Figure 4B. The data depicted in Figure 4C indicate that CD107a mobilization and the expression of TNFα and IFNγ occurred in the same cells.

**OCT4-specific IP-10 production by cells isolated from ovarian cancer patients.** We have previously demonstrated that ovarian cancer cells expressing both OCT4 and MYC constitute putative ovarian CSCs. As we detected OCT4-specific memory cells in healthy donors, we prospectively analyzed the presence of OCT4-specific memory cells in a cohort of ovarian cancer patients (Table S3). No patient pre-selection was made, and tests were run on subjects for which both ascites and PBMC samples were available. Both ascites-derived mononuclear cells (MNCs) and autologous PBMCs were stimulated for 48 h with the immunoreactive OCT4-derived peptide 74, followed by the assessment of IP-10 secretion in culture supernatants (Fig. 5). PHA and non-stimulated cells served as positive and negative controls, respectively. Similar to healthy donors, all 5 ovarian cancer patients tested exhibited measurable OCT4-specific IP-10 production, indicating the existence of OCT4-specific memory T cells in these individuals.

**Discussion**

The current study demonstrates that most healthy subjects, as well as patients bearing ovarian tumors, have naturally occurring memory T cells specific for OCT4 in their peripheral blood. Furthermore, we show that CD4+ OCT4-reactive T cells from healthy donors can be expanded and their CD8+ counterparts can be activated by specific OCT4 peptides in vitro. Upon
stimulation with autologous DCs loaded with OCT4-derived peptides or with the OCT4-coding mRNA, OCT4-specific CD4+ and CD8+ T cells secrete cytokines. Although it is tempting to assume that individuals would be completely tolerant to self proteins, the elimination of autoreactive T cells during negative selection in the thymus is not fool-proof, as demonstrated by the emergence of autoimmune diseases. These autoreactive T-cell clones are generally kept under control by Tregs or fail to be stimulated in vivo owing to low levels of antigen expression, in turn resulting in minimal degrees of presentation of the corresponding peptides on MHC molecules.35 However, during oncogenesis, several of these low-abundance proteins are overexpressed, which may drive the activation of T cells that actively infiltrate neoplastic lesions.36–41 Such autoreactive T cells can also be activated using different approaches in the context of anticancer immunotherapy.42–46 The importance of expression levels for the recognition of a given antigen by the immune system has recently been demonstrated.47 In particular, it has been shown that tumor-specific T cells fail to exert antineoplastic effects as melanoma cells dedifferentiate, resulting in the decreased expression of TAAs including gp100 and tyrosinase.47 The antigen expression level is hence of the utmost importance for determining whether T cells become reactive against malignant cells or remain quiescent. This concept has further been exemplified in a study that evaluated the immune responses to teratomas evoked by induced pluripotent stem cells, as it appeared that the increased expression of several normal proteins initiated adaptive immunity. However, not all overexpressed proteins elicited an immune response.

Figure 3. Detection of OCT4-reactive CD4+ T cells. MACS-sorted CD4+ cells were stimulated with autologous dendritic cells (DCs) loaded with an immunoreactive OCT4-derived peptide. CD4+ cells stimulated with anti-CD3/anti-CD28 beads and CD4+ cells exposed to unloaded DCs served as a positive and negative control condition, respectively. Results from 2 representative donors showing interferon γ (IFNγ) production (on day 3) and antigen-dependent CD4+ T-cell proliferation (on day 6) are reported. CD4+ cells from both donors did not exhibit high IFNγ production by in response to OCT4-derived peptide-loaded DCs (p > 0.05), while cells from one donor underwent a significant proliferative response (p < 0.05).
Figure 4. Detection of OCT4-reactive CD8+ T cells. (A–C) MACS-sorted CD4+ cells were stimulated with autologous dendritic cells (DCs) loaded with an immunoreactive OCT4-derived peptide. CD4+ cells stimulated with anti-CD3/anti-CD28 beads and CD4+ cells exposed to unloaded DCs served as a positive and negative control condition, respectively. (A) Results from one representative donor showing no significant interferon γ (IFN-γ) production (on day 3) and no antigen-dependent CD8+ T-cell proliferation (on day 6) (p > 0.05) are reported. (B) After 12 d of co-culture, a second stimulation was performed with derived peptide-loaded DCs. Thereafter, peptide-specific CD8+ T cells were analyzed for their cytotoxic functions by intracellular cytokine staining and flow cytometry. The expression of activation markers by cells from one representative healthy donor is shown, together with the gating strategy. (C) Results from one representative donor showing the mobilization of CD107a and the expression of IFN-γ and tumor necrosis factor α (TNF-α) by the same cells (gating strategy as in (B)) are shown.
suggesting that factors other than the expression level, such as the host MHC alleles, the subcellular location of TAAs and their degree of proteosomal degradation, also play a critical role in determining the intensity of immune responses.

In our study, the frequency of OCT4-reactive cells was quite low, indicating that these cells are not (or poorly) stimulated in vivo. Thus, OCT4 appears to be either not expressed or expressed at very low levels. In line with this notion, healthy individuals were shown to lack tolerance to some OCT4 epitopes. Interestingly, ovarian cancer patients harbor a small cancer cell population that expresses OCT4. As most, if not all, patient-derived peripheral lymphocytes were able to detect OCT4, OCT4+ ovarian cancer cells presumably do not reflect a lack of anti-OCT4 immune responses in these patients.

OCT4-specific T cells were detected even in the ascites of ovarian cancer patients. Apparently, these T cells are counterbalanced by strong suppressive mechanisms that operate in the abdomen.48–52 Natural immunity against proteins involved in pluripotency has previously been demonstrated. For example, Dhodapkar et al. have shown that OCT4-responsive T cells can be detected in the PBMCs of approximately 83% healthy donors and that these OCT4-specific cells mainly are CD4+ T cells. The same authors also found 38% of germ cell tumor patients to display measurable OCT4-specific T-cell immunity before chemotherapy, a fraction that increased to 83% upon treatment.53 Natural immune responses targeting the pluripotency-related protein SOX2 have also been reported. In particular, it has been shown that CD8+ SOX2-specific T cells are frequent in patients with monoclonal gammopathy of undetermined significance (MGUS). MGUS often precedes myeloma, but SOX2-specific T-cell immunity was not detectable in myeloma patients.54 Nevertheless, anti-SOX2 autoantibodies were detected in multiple myeloma patients upon allogeneic stem cell transplantation.55 OCT4 and SOX2 are crucial in regulating the self-renewal and pluripotency of ESCs, and both have recently been involved in the development of CSCs in various types of cancer.56–64 In some cases, OCT4 and SOX2 have been detected in the cytoplasm, a setting that is compatible with robust presentation on MHC Class I molecules.61 Although OCT4-specific cells were detectable in both healthy subjects and ovarian cancer patients, their reactivity was not comparable to that of normal memory T cells to recall antigens. As a result of very limited re-stimulation in vivo, OCT4-specific cells are hence likely remain in a quiescent state. Recently, a similar status has been reported for antitumor CTLs capable of inhibiting the expansion of naive and memory CD8+ T cells,65 and it has been suggested that a temporary blockade of these perforin-expressing antitumor CTLs could have huge effects on the DC-based enforcement of antitumor responses as well as on the adoptive transfer of T cells equipped with appropriate T-cell receptors.

The presence of OCT4-specific T cells in healthy individuals (without any signs of autoimmune disease) indicates that OCT4 is normally expressed at such low levels that it fails to stimulate T-cell activation and expansion. In line with this notion, the frequency of these cells was very low. Therefore, it seems safe to use OCT4 as a target antigen for the elicitation of therapeutic immune response. The fact that OCT4-specific T cells were detected in cancer-free individuals comforts the notion that the reactivity of their counterparts in cancer patients has not shifted to de novo epitopes. This said, the mechanisms that inhibit immune responses in the abdomen of cancer patients need to be overcome to enable the use of OCT4-targeting immunotherapeutic approaches.

**Materials and Methods**

**OCT4 peptides.** Dhodapkar et al. synthesized an OCT4-derived peptide library and tested T-cell reactivity to individual peptides. This library consisted of 95 peptides (15-mer overlapping by 11 amino acids).62 A highly T-cell immunoreactive peptide (number 74, DVF RVW FCN RRQ KGK), a non-immunoreactive peptide (number 57, WVE EAD NNE NLQ EIC) as well as an elongated version of peptide 74 (NRR DVF RVW FCN RRQ KGK VWF C) were purchased from JPT Peptide Technologies.

**In vitro OCT4 mRNA synthesis.** The plasmid pGEM4Z-5'UT-OCT4-3'UT-A64 was constructed by digestion of the full-length OCT4-containing plasmid pCR-TOPO-OCT4 (ImaGenes GmbH, BC117435) and pGEM4Z-5'UT-gp100–3'UT-A64 with EcoRI (Bioké, R3101L), followed by insertion of the OCT4-coding sequence into the empty pGEM4Z vector. Plasmids were amplified in Escherichia coli and isolated using the Nucleospin Plasmid QuickPure reagent (Macherey-Nagel, 740 615.250). This plasmid was linearized with SpeI (New England Biolabs, R0133S), purified by phenol/chloroform extraction plus ethanol precipitation and used as the template for mRNA synthesis with the mMESSAGE mMACHINE kit (T7 promoter, Applied Biosystems, AM1344), according to the manufacturer’s instructions.

**Stimulation and maintenance of OCT4-specific T cells.** Buffy coats were obtained from the local blood bank from
anonymous healthy donors after informed consent was obtained. Blood was donated in the afternoon, tested and processed. The next morning, the buffy coat was collected and immediately processed. PBMCs were isolated by density-gradient centrifugation using Lymphoprep (Axis-Shield PoC AS, N-1114547). Monocytes were purified from PBMCs following a 1 h adherence step at 37°C in X-VIVO 15 medium (Lonza, BE04-418Q) supplemented with 2% human serum (HS, Sigma, H1513, pre-tested for mycoplasma and virus). Non-adherent peripheral blood lymphocytes (PBLs) were washed with PBS and cryopreserved in X-VIVO 15 medium containing 2% HS and 10% DMSO for subsequent use. Adherent cells were cultured in X-VIVO 15 medium supplemented with 2% HS and 450 U/mL granulocyte macrophage colony-stimulating factor (GM-CSF, from CellGenix, 1412-050) and 300 U/mL IL-4 (Cellgenix, 1403-050). After 5–6 d of culture, DCs were matured for 2 d upon the administration of 2 μg/mL polynucleosinic-polycytidylic acid (polyIC, from Sigma Aldrich, P0913) and 4 μg/mL (R848, from Enzo Life Sciences-Axxora, ALX-420-038-MO25). On day 7 or 8, 2 × 10^6 mature DCs were pulsed for 3 h with 15 μg OCT4-derived peptides, or 10 × 10^6 mature DCs were electroporated with the OCT4 mRNA as described below. Then, DCs were co-cultured with MACS-sorted cryopreserved autologous CD4+ or CD8+ T cells at a DC: responder cell ratio of 1:30 (2 × 10^6 responder cells per well) in Iscove’s modified Dulbecco’s medium (IMDM, from Invitrogen, 21980-065) supplemented with 10% HS in 96-well plates. IL-2 (100 U/mL, Proleukin®) was added to the DC:T-cell co-cultures on day 6 and was subsequently added at 50 U/mL every 2–3 d. IL-7 (R&D Systems, 207-IL) and IL-15 (5 ng/mL, Biomol, 52619.10) were also added to the DC:CD8+ T cell cocultures from the beginning of the co-culture period and every 2–3 d thereafter. T cells co-cultured with unloaded autologous DCs were used as negative controls, and T cells stimulated with anti-CD3/anti-CD28 beads (Invitrogen, 111.31D) served as positive controls. To test the presence of OCT4-reactive CD8+ T cells, cells were restimulated with peptide-loaded autologous DCs and analyzed for functionality.

Electroporation of DCs. Mature DCs were washed twice with PBS and once with phenol-red free OptiMEM medium (Invitrogen, 11058-021). Twenty micrograms of mRNA were transferred to a 4-mm cuvette (Bio-Rad, 65-2089), and 8–10 × 10^6 cells were added in 180 μL of OptiMEM and incubated for 3 min before being pulsed in a GenePulser Xcell (Bio-Rad) with an exponential decay pulse of 300 V and capacitance of 150 μF. After electroporation, DCs were allowed to rest for at least 2 h at 37°C in phenol red-free X-VIVO 15 medium (Lonza, BE04-744Q) supplemented with 6% HS before further treatment.

Detection of CD137-expressing CD8+ T cells. To evaluate the CD137 expression by CD8+ T cells stimulated with OCT4-derived peptide-loaded DCs, 2 × 10^6 previously stimulated T cells were re-stimulated with autologous DCs loaded with an immunoreactive OCT4-derived peptide and cultured in 1 mL IMDM supplemented with 10% HS and 5 μg/mL anti-CD28/anti-CD49d co-stimulatory reagents (BD Biosciences, 347690). In every experiment, T cells activated with 1 μg/mL SEB (Sigma S4881) were used as a positive control, and a negative control (medium only) was included to monitor the spontaneous expression of CD137. After 5 h of stimulation, 3 μg/mL brefeldin A (BFA, Sigma, B6542) were added. After 16–18 h, cells were stained with anti-CD8-FITC conjugates (BD Biosciences, 555366), fixed with 4% paraformaldehyde, permeabilized with PBS containing 0.5% saponin plus 2% HS and stained with anti-CD137-APC conjugates (BD Biosciences, 550890). Flow cytometry was performed using a CyAn™ ADP cytometer (Beckman Coulter), and data were analyzed using the FlowJo software v. 9.2.

CD8+ T-cell intracellular cytokine detection and CD107a mobilization assay. To test the functionality of CD8+ T cells, 2 × 10^6 CD8+ cells previously exposed to autologous DCs loaded with an immunoreactive OCT4-derived peptide were re-exposed to the same conditions and incubated in 1 mL IMDM containing 10% HS, 5 μg/mL anti-CD28/anti-CD49d reagents, 1 μL/mL monensin (eBioscience, 00-4505-51) and 10 μg/mL BFA. The same positive and negative controls described above were used. Anti-CD107a-Alexa Fluor® 700 conjugates (BD, 561340) were added at the beginning of the co-culture, and 5 h later cells were collected and stained with the Fixable Viability Dye eFluor® 780 (eBioscience, 65-0865-18) and anti-CD8-APC conjugates (BD, 555369). Finally, cells were fixed, permeabilized and stained with anti-IFNγ-PerCP-Cy5.5 (eBioscience, 560704) conjugates and analyzed by flow cytometry.

ELISA. The concentration of IFNγ in co-culture supernatants was measured by using of conventional ELISA approach. Briefly, ELISA plates (NUNC, 155382) were coated overnight with a monoclonal antibody specific for human IFNγ (Thermo Scientific Pierce Antibodies, M700A), blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich, A3294) and washed with PBS containing 0.05% Tween 20 (Merck, 8.22184.0500). Then, cell culture supernatant were added and incubated at room temperature for 1 h. After washing, a biotinylated detection antibody (Thermo Scientific Pierce Antibodies, M701B) was added and allowed to incubate for 1 h at room temperature. Finally, plates were washed and a streptavidin-conjugated horseradish peroxidase (Thermo Scientific Pierce Antibodies, C21135) was added for 30 min, followed by incubation with the substrate 3,3',5,5'-tetramethylbenzidine (Sigma, T2885). The reaction was stopped with 0.8 M H2SO4, and the absorbance at 450 nm was measured using an ELISA plate reader (Bio-Rad). IP-10 levels in co-culture supernatants were measured using the human CXCL10/IP-10 DuoSet ELISA kit (R&D Systems, DY266), according to the manufacturer’s instructions.

Detection of OCT4-reactive T cells in PBMCs from healthy donors and patients. The ascites of patients with ovarian cancer were obtained during debulking surgery. The ascitic fluid was processed immediately at room temperature or—when the surgery was performed in the afternoon—was stored overnight at 4°C and then processed the next morning. Institutional guidelines for the collection of human material were followed. Blood was obtained from healthy donors and cancer patients after informed consent was obtained. Blood samples were taken during or shortly after surgery and were also processed at room temperature within 24
of collection. Ascites-derived monoclonal cells and PBMCs (from both healthy donors and patients) were isolated by density-gradient centrifugation using Lymphoprep. Then, 2 × 10^5 cells were cultured in IMDM supplemented with 10% HS and 10 μg/mL peptide 74, 10 μg/mL peptide 57 or 5 μg/mL PHA. Cells cultured in medium only provided negative control conditions. After 48 h, supernatants were collected and measured for the production of IP-10 by ELISA. In some experiments, the production of intracellular IP-10 was also measured. In this case, cells were collected, washed, labeled with anti-CD8-FITC conjugates and then fixed, permeabilized and labeled with anti-IP-10-PE conjugates (R&D Systems, IC266P) prior to analysis by flow cytometry.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
This work was supported by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, FES0908).

Supplemental Material
Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/article/24271/
